Idera Pharmaceuticals is part of the biotechnology industry and is in the healthcare sector. The company CEO is Vincent J. Milano. Idera Pharmaceuticals Inc is a clinical stage biotechnology company. It is engaged in the discovery, development and commercialization of novel therapeutics for oncology and rare diseases.



Previous Intraday Performance:

The IDRA shares had a previous change of 1.98% which opened at 2.56 and closed at 2.57. It moved to an intraday high of 2.60 and a low of 2.46.

SeekingAlpha:  Midday Gainers / Losers

Historical Performance:

Over the last five trading days, IDRA shares returned 0.39% and in the past 30 trading days it returned 0.00%. Over three months, it changed -9.51%. In one year it has changed -83.27% and within that year its

52 week high was 17.04 and its 52 week low was 2.25. IDRA stock is 14.22% above its 52 week low.

Our calculations result in a 200 day moving average of 5.07 and a 50 day moving average of 2.77. Right now, IDRA stock is trading -49.34% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  Midday Gainers / Losers

Liquidity:

The company has a market cap of $72.0m with 28.0m shares outstanding and a float of 26.6m shares. Trading volume was 330,440 shares and has experienced an average volume of 471,713 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for Idera Pharmaceuticals was -2.27 which ended on 31st of December 2018. Based on 4 analyst estimates, the consensus EPS for the next quarter is -0.46.

Below was the last reported quarterly diluted earnings per share:

1stQtr 2019 -0.40
4thQtr 2018 -0.45
3rdQtr 2018 -0.43
2ndQtr 2018 -0.59
1stQtr 2018 -0.81

The long-term trend of the EPS is an important number as it indicates the present value of Idera Pharmaceuticals; it is usually expressed as a percentage and is then referred to as the EPS growth rate, which at this time is hard to estimate, but revenue growth has been -59.50% over the last twelve months.



Indicators Also to Watch:

Based on the latest filings, there is 59.60% of institutional ownership.

The beta was calculated to be 2.51.

SeekingAlpha:  UK regulator to open more BT infrastructure for fiber

Fundamental Numbers:

Based on last reported financials, the company’s return on assets is -61.98%, price-to-sales is 173.50 and price-to-book is 1.27.

Company Score Card:

Results are out of six:
 5  : Growth Expectations Result
 5  : Financial Safety Result
 0  : Past Performance Result
 1  : Valuation Result
 0  : Dividend Safety Result
 2  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here